Cellectar Biosciences Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $3.42 on 06/13/24 and the lowest value was $0.22 on 12/19/24.
52-week price history of CLRB Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Cellectar Biosciences Inc’s current trading price is -89.45% away from its 52-week high, while its distance from the 52-week low is 61.07%. The stock’s price range during the 52-week period has remained between $0.22 and $3.42. In the Healthcare sector, the company’s shares saw a trading volume of around 8.86 million for the day, which was evidently lower than the average daily volume of 11.36 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Cellectar Biosciences Inc (CLRB) has experienced a quarterly rise of 13.46% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 16.63M and boasts a workforce of 11 employees.
Making Sense of Trading Volume and Moving Average Data
Examining CLRB’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CLRB stands at 0.05. Similarly, the long-term debt-to-equity ratio is also 0.04.
CLRB Stock Price Performance Analysis
Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. The index has shown a price gain of 20.67% this year. Over the last six months, there has been a stronger performance of -75.29%. The price of CLRB fallen by 47.75% during the last 30 days period. For the last 5-days stocks have improved 41.49%.
